Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico

Table 4 Parameters of primary and recurrent Plasmodium vivax blood infections from T14 patients

Patient	Age/sex	Primary blood infection		Recurrent infection by microcopy					Serology (ELISA OD value/405NM)	mg/kg bw administered
Patient	Age/sex	Asexual parasitaemia (p/µl)	RFLP: cspr-msp3α/β	Day^a	Presence of clinical symptoms	Asexual parasitaemia: (p/µl)		Genotype cspr-msp3α/β	Serology (ELISA OD value/405NM)	CQ	PQ
P3	24/M	3177	vk210-B/III	D210	Yes	9327^b	vk210-B/III		0.12_D183 → 0.62 _D210	25.86	3.62
P47	14/M	2119	vk210-A/I	D249	No	Mc-PCR-	–		0.08_D187 → 1.12 _D249	30.0	4.2
P47	14/M	2119	vk210-A/I	D279	Yes	3845^b	vk210-A/I		→0.75_D279	30.0	4.2
P57	50/M	2784	Vk210-K/IV	D216	Yes	2706^b	vk210-K/IV		0.324_D90 → 1.405_D216	21.42	3.0
P61	21/F	836	Vk210-A	D95	No	Mc-/PCR−	–		0.49_D65 → 1.67_D95	28.84	4.03
P61	21/F	836	Vk210-A	D313	No	Mc-/PCR+	–		→1.27_D313	28.84	4.03

M male, F female, RFLP restriction fragment length polymorphism, cspr circumsporozoite repeat type, msp3α merozoite surface protein 3α/β
^aDay of visit/sample and diagnosis
^bRDT positive and T14 given; Mc microscopy, PCR molecular diagnosis; recommended treatment: a total dose of 25 mg CQ and 3.5 mg PQ/kg bw; bw body weight

ISSN: 1475-2875